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Abstract
Background: The multicentre randomised controlled PEPaNIC trial showed that withholding parenteral nutrition
(PN) during the first week of critical illness in children was clinically superior to providing early PN. This study describes
the cost-effectiveness of this new nutritional strategy.
Methods: Direct medical costs were calculated with use of a micro-costing approach. We compared the costs of late
versus early initiation of PN (n = 673 versus n = 670 patients) in the Belgian and Dutch study populations from a hospital
perspective, using Student’s t test with bootstrapping. Main cost drivers were identified and the impact of new infections
on the total costs was assessed.
Results: Mean direct medical costs for patients receiving late PN (€26.680, IQR €10.090–28.830 per patient) were 21%
lower (-€7.180, p = 0.007) than for patients receiving early PN (€33.860, IQR €11.080–34.720). Since late PN was more
effective and less costly, this strategy was superior to early PN. The lower costs for PN only contributed 2.1% to the
total cost reduction. The main cost driver was intensive care hospitalisation costs (-€4.120, p = 0.003). The patients who
acquired a new infection (14%) were responsible for 41% of the total costs. Sensitivity analyses confirmed consistency
across both healthcare systems.
Conclusions: Late initiation of PN decreased the direct medical costs for hospitalisation in critically ill children, beyond
the expected lower costs for withholding PN. Avoiding new infections by late initiation of PN yielded a large cost reduction.
Hence, late initiation of PN was superior to early initiation of PN largely via its effect on new infections.
Trial registration: ClinicalTrials.gov, NCT01536275. Registered on 16 February 2012.
Keywords: Parenteral nutrition, Cost-effectiveness, Health economics, Costs, Intensive care
Background
Healthcare costs are growing worldwide. Intensive care is
responsible for a substantial proportion of all healthcare
expenses, particularly prolonged intensive care and pallia-
tive care [1–4]. Intensive care costs are largely dependent
on length of stay (LOS) in the intensive care unit (ICU),
which is strongly influenced by complications, such as
hospital-acquired infections [5].
Recently, a multicentre, randomised, controlled,
parallel-group, superiority trial, with the acronym PEPa-
NIC (n = 1.440) concluded that withholding parenteral
nutrition (PN) during the first week of critical illness in
children was clinically superior to providing PN within
24 hours when enteral nutrition was insufficient [6],
resulting in fewer patients with new infections. Aside
from this clinical benefit, an additional economic benefit
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of late PN would be an extra argument for implementa-
tion of this new nutritional strategy.
Currently, no studies have investigated costs of different
timing of initiation of PN in children in the paediatric
ICU (PICU). Our cost-effectiveness analysis was prede-
signed, offering a unique opportunity for a micro-costing
approach [7]. With this method of calculating hospital
costs, all relevant cost categories are included and costs
are calculated at the most detailed level per patient, in
contrast to the gross-costing approach, whereby the cost
categories are highly aggregated or only hospitalisation
costs are included.
We hypothesised that withholding PN for one week is
a cost-saving strategy comprising more than merely
omitting the costs of PN itself. The aims of this study
were (1) to compare total direct medical costs of early
versus late initiation of PN in the PICU from a hospital
perspective in an international context, (2) to provide
detailed insight into the distribution of cost components,
and (3) to assess the impact of acquiring a new infection
in the PICU on direct medical costs.
Methods
Context
A total of 1440 critically ill children, aged 0 (term neonates)
to 17 years, from three large tertiary referral PICUs in three
countries (University Hospitals Leuven in Belgium, Eras-
mus MC in The Netherlands, and Stollery Children’s Hos-
pital in Canada) were randomly assigned to early initiation
of PN (standard care) or late initiation of PN (intervention).
Initiation and dose of enteral nutrition (EN) and the admin-
istration of trace elements, minerals and vitamins were
identical in both groups. Patients assigned to the group
with late initiation of PN (n = 717) received no PN during
the first week of critical illness. Patients assigned to the
group with early initiation of PN (n = 723) received PN
within 24 hours, according to the local standards. After the
first week, when patients were still in the PICU and EN
was insufficient to meet nutritional goals, PN was adminis-
tered equally in both groups according to standard nutri-
tion protocols [6, 8]. The institutional ethical review boards
of the participating centres in Leuven (ML8052), Rotterdam
(NL38772.000.12) and Edmonton (Pro00038098) approved
the study, which was performed in accordance with
the 1964 Declaration of Helsinki and its amendments.
Written informed consent was obtained from the par-
ents or legal guardians.
In this study, we explored the total direct medical
costs, from a hospital perspective, in the Belgian and
Dutch study populations, as these healthcare systems are
reasonably comparable. Including the patients from
Canada would introduce a bias, as cost calculations and
reimbursements are too differently structured in Anglo-
Saxon healthcare systems. Therefore, we excluded this
centre from the cost analyses.
Healthcare systems
In the Dutch healthcare system, hospitals are mainly paid
by private insurance companies according to tariffs based
on “Diagnosis Therapy Combination” (DBC) [9]. However,
registered DBCs per patient do not represent individua-
lised healthcare consumption. As the tariffs are fixed, spe-
cific healthcare activities are not presented in the patients’
invoices. Therefore, we used individual healthcare con-
sumption and corresponding unit prices, which are regis-
tered by the hospital for reporting and stock management.
In Belgium, healthcare costs are reimbursed by sickness
funds and private insurance companies. Since all health-
care activities are represented in the patients’ invoices,
these invoices can be used to accurately quantify health-
care consumption. However, total healthcare costs are
mainly covered by advance payments to the hospital,
directly by the government. Consequently, for healthcare
activities for which the hospital receives these advance
payments, only 25% of the costs are represented in the
patients’ invoices. When this is corrected to 100%, they
reflect real healthcare costs from a hospital perspective [10].
Resource consumption
The participating clinicians filled out standardised case
report forms during the ICU stay, including duration of
ICU dependency, post-ICU hospitalisation, mechanical
ventilation, renal replacement therapy (RRT) and mech-
anical hemodynamic support. LOS encompassed both
index and transferral hospitals. PN consumption was
obtained from the study database for Dutch patients and
from the invoices for Belgian patients. Detailed informa-
tion on diagnostic procedures, medication, blood prod-
ucts, surgery and consultations were obtained from the
data management system of the hospital for Dutch
patients and from the invoices for Belgian patients.
Healthcare consumption was divided into ten cost cat-
egories: (1) ICU hospitalisation (both index and transferral
hospital); (2) post-ICU hospitalisation (both index and
transferral hospital); (3) PN; (4) medication; (5) laboratory
diagnostics; (6) other diagnostics; (7) ventilator support;
(8) RRT and mechanical haemodynamic support; (9)
surgery; and (10) consultations from other specialists.
Economic evaluation
The cost-effectiveness analyses were based on the Dutch
and Belgian guidelines for performing costs studies [10, 11].
Furthermore, this study is in line with the international
Consolidated Health Economic Evaluation Reporting Stan-
dards (CHEERS) statement [12]. Real medical costs were
calculated by multiplying the volumes of healthcare use
with the corresponding unit prices. Costs were calculated
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during two periods. From randomisation until ready-for-
discharge from ICU, or death, the costs in all aforemen-
tioned cost categories were calculated. Ready-for-discharge
was a priori chosen to avoid bias due to availability of beds
on regular wards and was defined as “no longer requiring
or no longer at risk for requiring vital organ support”. From
ready-for-discharge from ICU until discharge from hospital,
only hospitalisation costs were calculated. If a patient was
transferred to another hospital, only hospitalisation costs
were included for the period from discharge from the index
hospital until discharge from the transferral hospital or
death. Since the time horizon was less than one year, unit
prices were not discounted.
In the Netherlands, the unit prices were available from
the hospital’s financial database, and were adjusted to
the year 2014. For hospital days (non-ICU), a national
guiding price per day was used, because children were
referred to different hospitals, charging different prices
[11]. The daily costs of mechanical ventilation and RRT
were estimated based on published literature [13, 14].
Production costs of infusions for the intervention group
were calculated by summing the costs of the PN ingredi-
ents, pharmacy compounding costs and additional trial
intervention costs.
In Belgium, financial data were registered by the billing
and warehousing collaborators of the index hospital as
this is standard procedure for invoicing. The unit prices
were official, nationally fixed prices adjusted to the year
2014, and were converted to 100%, if necessary, to obtain
real costs from a hospital perspective [10]. There were no
additional trial intervention costs for infusions in the
group receiving late initiation of PN.
Costs of medication were categorised according to the
first level of the Anatomical Therapeutic Chemical (ATC)
classification, which is the World Health Organisation
(WHO) tool for drug utilisation research [15]. Each drug
has its unique ATC code and price. Costs for ATC code
B05BA (PN solutions) were reported separately. Since we
were unable to distinguish costs per ATC code in Dutch
patients, we excluded them from this ATC code analysis.
However, since new infections were a primary outcome in
the trial, we analysed the costs of anti-infective drugs in
both centres.
Study endpoints
The primary endpoint was the difference in total direct
medical costs, from a hospital perspective, between early
and late initiation of PN. Furthermore, the ten cost cat-
egories were analysed separately. In order to give insight
into costs among different groups of patients, we com-
pared total direct medical costs of early initiation of PN
with late initiation of PN in the stratification groups as
used for the PEPaNIC trial: “Surgical cardiac”, “Surgical
other”, “Medical neurological” and “Medical other”, and
age groups younger and older than one year [8]. Addition-
ally, the drugs responsible for differences in medication
costs were investigated based on the ATC codes. Also, the
impact of new infections on total costs was calculated.
Finally, we explored the cost-effectiveness of late initiation
of PN, using the number of patients with a new infection
prevented in the ICU as an effect measure.
Statistical analyses
The PEPaNIC trial was a priori statistically powered to
detect a difference in new infections. Therefore, the stat-
istical power to detect differences in total direct medical
costs was dependent on the number of patients enrolled
in the original PEPaNIC trial. This cost analysis was an a
priori planned secondary analysis.
Costs were reported in euro (€), as mean (SD and IQR),
as recommended for cost analyses [16]. IQR was reported,
as cost data is always highly skewed, and IQR reflects the
statistical dispersion more realistically than standard devi-
ation or standard error. Other data were reported as mean
(SE), median (IQR) or number (%), as appropriate. In
order to check whether the major costs were similarly dis-
tributed into the cost categories in both centres, a Pareto
analysis was performed. This is a chart to demonstrate
which factors are contributing most to a problem (i.e. total
costs) [17].
Costs were compared univariably using Student’s one-
tailed t test with bootstrapping (×1000) [16], LOS was
compared using the Mann-Whitney U test, and the inci-
dence of new infection was compared using Fisher’s exact
test. Based on the clinical results that point out clearly
that late PN reduces resource consumption by reduction
of new infections and shorter PICU stay, we have chosen
to test the differences in costs one-sided, hypothesising
that late PN is less costly than early PN. One-sided p
values <0.05 were considered statistically significant. Ef-
fects were reported as mean difference or odds ratio (OR)
with the corresponding 95% confidence interval (CI). The
OR for acquiring a new infection was adjusted for age, risk
of malnutrition (STRONGkids group), treatment centre,
admission diagnosis, and degree of organ failure (PeLOD
score), in line with the PEPaNIC trial [6], and also Paediat-
ric Index of Mortality 2 (PIM2) score to adjust for risk of
mortality. The adjusted OR was analysed using binary
logistic regression. Analyses were conducted using IBM
SPSS statistics, version 24.0.
Sensitivity analyses
Sensitivity analyses were conducted as follows:
1. The total costs were analysed using prices from the
Belgian healthcare system for all patients.
2. The total costs were analysed using prices from the
Dutch healthcare system for all patients.
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3. The total costs were analysed separately in the
Belgian patients.
4. The total costs were analysed separately in the
Dutch patients.
5. As only the hospitalisation costs of the post-ICU
period were included in the primary analysis, the
additional post-ICU costs (i.e. laboratory, medication
costs) were left out. Since this could underestimate
our results, the estimated additional post-ICU costs
were added in the third sensitivity analysis. These
additional post-ICU costs were estimated based on
the invoices of the Belgian patients.
Results
We compared the total direct medical costs of late initi-
ation of PN (N = 673 patients) with those of early initi-
ation of PN (N = 670 patients) in the Dutch and Belgian
study populations. The patients’ baseline characteristics
and main clinical outcomes are described in Table 1.
Total healthcare costs and evaluation of cost drivers
Late initiation of PN, as compared with early initiation
of PN, reduced the mean total direct medical costs by
€7.180 (95% CI (-€12.920; -€1.880), p = 0.007) per patient
(early initiation of PN €33.860, late initiation of PN
€26.680), which is a saving of 21% (Table 2).
The major costs were divided into cost categories
similarly for both centres (Additional file 1). Differences
in mean costs between Belgian and Dutch patients were
due to shorter duration of stay in the ICU (factor 0.55)
in Belgian patients (p < 0.001), which might be caused by
differences in patient populations. In contrast, the
Belgian costs per day in ICU (mean costs of all categor-
ies summed, except hospitalisation costs post-ICU,
divided by the duration of ICU stay) were higher (factor
Table 1 Baseline characteristics and main clinical outcomes
Early PN
(N = 670)
Late PN
(N = 673)
Baseline characteristicsa
Median age (IQR), years 1.3 (0.3–6.0) 1.4 (0.2–7.0)
Age <1 year, n (%) 311 (46.4) 312 (46.4)
Male sex, n (%) 386 (57.6) 393 (58.4)
STRONGkids risk level, n (%)b
Medium 593 (88.5) 600 (89.2)
High 77 (11.5) 73 (10.8)
Median PeLOD score, first 24 hours in paediatric ICU (IQR)c 21 (12–32) 21 (11–31)
Median PIM2 score (IQR)d -2.8 (-3.7; -1.3) -2.8 (-3.7; -1.6)
Emergency admission, n (%) 325 (48.5) 308 (45.7)
Diagnostic group, n (%)
Surgical cardiac 264 (39.4) 259 (38.5)
Surgical other 202 (30.1) 205 (30.4)
Medical neurological 44 (6.6) 50 (7.4)
Medical other 160 (23.9) 159 (23.5)
Condition on admission, n (%)
Mechanical ventilation required 596 (90.0) 587 (87.2)
ECMO or other mechanical hemodynamic support required 16 (2.4) 22 (3.3)
Infection 256 (38.2) 244 (36.3)
Clinical primary outcomes P valuee
New infections, n (%) 120 (17.9) 71 (10.6) <0.001
Median duration of stay in paediatric ICU (IQR), dayse 4 (2–9) 3 (2–7) 0.002
PN parenteral nutrition, STRONGkids Screening Tool for Risk on Nutritional Status and Growth, PeLOD Paediatric Logistic Organ Dysfunction, PIM2 Paediatric Index
of Mortality 2, ECMO extracorporeal membrane oxygenation, ICU intensive care unit
aThere were no significant differences in characteristics between treatment groups at baseline
bSTRONGkids scores range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score of 4 to 5
indicating high risk
cPeLOD scores range from 0 to 71, with higher scores indicating more severe illness
dPIM2 scores, with higher scores indicating a higher risk of mortality
eThe duration of stay in the paediatric ICU was defined as the time from admission until the patient was ready for discharge (i.e., the patient no longer required
or was no longer at risk of requiring vital-organ support). The duration of stay was not censored, nor adjusted for death
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1.18) than the Dutch costs (p < 0.001). Almost all cost
categories showed lower costs with late initiation of PN
than with early initiation of PN. The largest reduction was
in ICU hospitalisation costs (-€4.120, 95% CI (-€7.590;
-€1.500)), medication costs (-€650, 95% CI (-€1.360;
€100)), and ventilator support costs (-€640, 95% CI
(-€1.260; -€190)) (Table 2). This reduction in costs is in
line with the shorter ICU stay in the group receiving late
initiation of PN (Table 1). PN costs were responsible for
2.1% (-€150, 95% CI (-€200; -€110)) of the reduction in
total costs.
The age category (<1 year versus ≥1 year) was not
apparently related to proportional cost reduction with late
initiation of PN (Additional file 2). Patients admitted for a
medical reason other than neurological disease had the
largest cost reduction with late initiation of PN (-€14.720,
95% CI (-€30.720; €130), p = 0.04) (Additional file 3).
Patients admitted for non-cardiac surgery also had cost
reduction with late initiation of PN (-€9.490, 95% CI
(-€20.720; €1.040), p = 0.05) (Additional file 3). Further-
more, 26% of the patients had a prolonged ICU stay
(>7 days), accounting for 60% of the costs. Moreover, the
most expensive 1% of patients accounted for 13% of the
total costs.
The distribution of medication costs is described in
Table 3. The combination of medications of category B
(blood and blood forming organs), containing PN solutions,
and category J (anti-infectives), containing antibiotics, was
responsible for 80% of the reduction in medication costs
with late initiation of PN (Table 3).
Impact of new infections
The proportion of patients with a new infection acquired
in the ICU was smaller with late initiation of PN than
with early initiation of PN (patients included for cost
analysis, 10.6% and 17.9%, respectively, p < 0.001)
(Table 1), with a corresponding adjusted odds ratio of
0.51 (95% CI (0.36; 0.71)). In the whole group, 1.2% of
the least expensive 50% of patients had acquired a new
infection compared to 28.5% of the most expensive 50%
of patients. Moreover, 85% (11 patients) of the most
expensive 1% of patients (13 patients) had acquired a
new infection. Figure 1 depicts the cost tree of patients
with and without a new infection in both randomisation
groups. In patients who acquired a new infection, costs
were increased from €21.350 to €91.200 (difference
€69.850, 95% CI (€50.700; €91.560), p = 0.001) with early
initiation of PN and from €20.600 to €78.210 (difference
€57.610, 95% CI (€41.890; €73.970), p = 0.001) with late
initiation of PN, predominantly caused by ICU hospital-
isation costs (early-PN group, difference €37.210, 95% CI
(€26.200; €52.750), p = 0.002; late-PN group: difference
€27.530, 95% CI (€20.660; €34.940), p = 0.001).
Late initiation of PN was more effective and less costly
than early initiation of PN, and falls into the south-eastern
quadrant of the cost-effectiveness plane. Interventions in
this quadrant are always considered cost-effective [18, 19].
Sensitivity analyses
The primary results were robust, as they could be repro-
duced with multiple sensitivity analyses (Table 4). Using
the Dutch or Belgian unit prices for all patients showed a
cost difference of late versus early PN of -€8.690 respect-
ively -€6.090, which is within the 95% CI of the primary
analysis of the base case ((-€12.920; -€1.880). Also, when
analysing the Dutch and Belgian patients separately, the
cost reduction with late PN was within the 95% CI of the
primary analysis of the base case (Table 4). The difference
Table 2 Healthcare costs split by major cost categories
Cost category Early PN, € Late PN, € Mean difference
(95% CI), €
P value
(t test)
Mean SD p25–p75 Mean SD p25–p75
ICU hospitalisation 13.710 35.130 2.270–13.250 9.590 16.730 2.270–9.070 -4.120 (-7.590; -1.500) 0.003
Medication 1.810 7.430 250–1000 1.160 3.080 220–830 -650 (-1.360; 100) 0.03
Ventilator support 1.740 6.650 150–1.430 1.100 2.300 150–1.070 -640 (-1.260; -190) 0.03
Post-ICU hospitalisation 7.140 14.530 1.500–6.900 6.560 14.270 1.500–6.270 -580 (-2.100; 1.080) 0.24
Surgery 4.760 5.480 280–6.500 4.240 4.260 200–6.280 -520 (-1.080; 10) 0.03
Laboratory diagnostics 2.290 4.090 540–2.160 1.820 3.370 440–1.820 -460 (-860; -40) 0.01
PN 300 500 60–300 150 270 20–170 -150 (-200; -110) <0.001
Other diagnostics 690 2.020 80–550 610 1.610 80–430 -80 (-290; -110) 0.20
Consultations 470 690 40–680 440 630 30–680 -30 (-100; 50) 0.19
RRT and mechanical hemodynamic support 950 6.740 0–0 1.010 9.370 0–0 60 (-810; 1.020) 0.45
Total 33.860 57.610 11.080–34.720 26.680 35.850 10.090–28.830 -7.180 (-12.920; -1.880) 0.007
Cost categories were ranked according to the mean difference between the treatment groups
PN parenteral nutrition, CI confidence interval, ICU Intensive Care Unit, RRT renal replacement therapy, p25–p75 25th to 75th percentile
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in absolute costs between the centres was predominantly
due to more resource consumption in the Dutch patients
(i.e. longer LOS) (Additional file 4). In the third sensitivity
analysis, total post-ICU costs were estimated and added to
the total ICU costs. Post-ICU costs were predominantly
hospitalisation costs (85%), which were already included
in the base case. Consequently, the additional post-ICU
costs of approximately €1.100 in this sensitivity analysis
represented the 15% of post-ICU costs that were not in-
cluded in the base case.
Discussion
This cost-effectiveness study of the PEPaNIC trial showed
that the total direct medical costs were considerably lower
when PN was withheld during the first week of critical
illness in children as compared with early initiation of PN.
Table 3 Medication costs of Belgian patients split by Anatomical Therapeutic Classification (ATC) system classes
ATC code Early PN, € Late PN, € Mean difference
(95% CI), €
P value
(t test)Mean SD p25–p75 Mean SD p25–p75
B (blood/blood forming organs) 850 1.820 210–740 580 1.350 140–480 -270 (-510; -40) 0.02
J (anti-infectives)a 320 2500 4–90 170 1.030 4–50 -150 (-470; 80) 0.17
A (alimentary tract/metabolism) 70 250 20–70 50 80 10–40 -30 (-40; -10) <0.001
V (various) 100 140 20–140 80 110 20–110 -20 (-40; -7) 0.004
N (nervous system) 90 180 30–80 70 150 30–80 -20 (-40; 0) 0.03
C (cardiovascular) 55 150 3–50 45 100 1–50 -10 (-30; 5) 0.07
R (respiratory) 20 150 0–0 10 50 0–0 -10 (-30; 7) 0.10
H (hormonal) 30 110 0–30 20 60 0–30 -10 (-20; 3) 0.10
M (musculo-skeletal) 13 40 3–10 7 10 3–9 -5 (-10; -2) 0.01
D (dermatologics) 10 70 0–8 7 30 0–8 -3 (-10; 3) 0.26
S (sensory organs) 3 5 0–4 2 3 0–4 -1 (-1; 0) 0.01
P (antiparasitic) 1 20 0–0 0 0 0–0 1 (-3; 0) 0.19
G (genito-urinary/sex hormones) 1 8 0–0 1 8 0–0 0 (-1; 1) 0.48
L (antineoplasmic/immunomodulating) 25 330 0–0 45 320 0–0 20 (-30; 60) 0.26
Total 1.600 4.663 380–1.260 1.070 2.577 310–830 -500 (-1.060; 20) 0.03
Cost categories were ranked according to the mean difference between the treatment groups. PN parenteral nutrition, CI confidence interval, p25–p75 25th to
75th percentile
aData from both Belgian and Dutch patients
Fig 1 Costs of patients with or without new infections. PN parenteral nutrition, pp per patient
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This cost reduction was mainly due to lowering of ICU
hospitalisation costs, although most cost components
were reduced by not using early PN. The reduction of the
costs for PN was responsible for only 2.1% of the total
cutback of costs, which supported our hypothesis that the
health-economic impact of withholding PN encompassed
more than the omission of costs for PN itself. Taking into
account the beneficial clinical impact of late initiation of
PN, we can conclude that withholding PN in the first
week of critical illness is superior to early initiation of
PN largely by preventing new infections, which is
cost-saving [18, 19].
Our results confirmed previously published results of
studies in critically ill adults that have compared early
with late initiation of PN [20, 21]. The American Thor-
acic Society has included “‘withholding PN for one week
in critically ill adults” in the top five recommendations
to improve healthcare while reducing healthcare costs
[22]. One other cost analysis of the timing of PN in
adults identified no difference in LOS, and US$ 3.170
higher costs per patient with late initiation of PN. How-
ever, the estimated costs in this study were based on a
Monte Carlo simulation, in which the estimated prob-
abilities of events, such as mechanical ventilation, have a
large impact on cost differences [23]. A micro-costing
approach, used in our study, provides more precise and
more reliable results, as this method uses the real costs
that have been incurred.
Three studies of paediatric ICU costs have been previ-
ously published, which allow comparison with our study
results. First, Harron et al. reported ICU stay and direct
ICU costs that are comparable to those we reported here,
which supports the generalisability of the findings of our
study [24]. Second, the CHiP study reported hospital costs
during a 12-month period (~ £21.000) [4] that were
slightly lower than those found in our study. These
differences could be explained by different study popula-
tions, with more patients included after cardiac surgery,
which may incur lower costs than medical or non-cardiac
surgical paediatric ICU patients, and more patients with
less organ failure, reflected by mean PeLOD of 7.5 as com-
pared with a median PeLOD of 21 in our study. Third,
Morillo-García et al. reported higher costs for children
with a nosocomial infection, as compared with those with-
out a new infection [25], which supports our conclusion
that healthcare costs can be reduced by preventing new
infections.
In line with previous research [26], we observed that
the duration of ICU stay had a major effect on the costs.
This was also reflected in the finding that patients with a
prolonged ICU stay, the minority of the total patient
population that was included, accounted for the majority
of the costs.
The reduction in medication costs with late versus early
initiation of PN was mainly due to lower use of products
in ATC categories B (blood and blood-forming organs)
and J (anti-infectives). This corroborates the finding that
late initiation of PN reduces the proportion of patients
with new infections, as it also does in adults [21]. Add-
itionally, patients with a new infection had higher total
costs per patient than those without a new infection. The
fact that the proportion of patients with new infections
increased from 1.2% among the least expensive patients to
85% among the 1% most expensive patients pointed to an
effect of new infections on the total costs. Therefore, redu-
cing the number of ICU days by preventing the occur-
rence of new infections by late initiation of PN seems to
have had most influence on the cost reduction.
The strength of this study is the micro-costing ap-
proach, reflecting real costs that incurred. Additionally,
our findings appeared robust across two healthcare sys-
tems. We have carefully checked whether combining the
Table 4 Sensitivity analyses
Early PN, € Late PN, € Mean difference
(95% CI), €
P value
(t test)
N Mean SD p25–p75 N Mean SD p25–p75
Primary analysis (total ICU costs and
post-ICU hospitalisation costs)
670 33.860 57.600 11.080–34.720 673 26.680 35.850 10.090–28.830 -7.180 (-12.920; -1.880) 0.007
Sensitivity analyses
1. Belgian unit pricesa 670 28.380 41.210 10.460–29.880 673 22.290 24.960 9.320–25.390 -6.090 (-9.950; -2.480) <0.001
2. Dutch unit pricesb 670 37.960 62.120 12.570–38.350 673 29.270 37.180 11.560–32.390 -8.690 (-14.090; -3.190) 0.003
3. Belgian patients 373 22.930 22.460 10.060–23.780 377 17.600 15.920 9.150–19.700 -5.330 (-8.650; -2.360) 0.003
4. Dutch patients 297 47.580 78.820 14.860–46.410 296 38.250 48.630 12.790–42.380 -9.330 (-20.410; 1.250) 0.04
5. Total ICU and total post-ICU costsc 670 34.990 58.316 11.470–35.580 673 27.800 36.859 10.530–30.580 -7.190 (-12.420; -1.970) 0.002
PN parenteral nutrition, CI confidence interval, ICU Intensive Care Unit
aThe total costs were analysed using prices from the Belgian healthcare system for all patients
bThe total costs were analysed using prices from the Dutch healthcare system for all patients
cIn the primary analysis, only the hospitalisation costs of the post-ICU period were included. The estimated additional post-ICU costs (i.e. laboratory, medication)
were added. These additional post-ICU costs were estimated based on the invoices of the Belgian patients
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Dutch and Belgian populations would compromise our
results by performing sensitivity analyses, which have
shown unanimously a cost reduction with late PN, which
was well within the range of the confidence interval of
the base case. These results may support that the inter-
national character of this study increased external validity
and, possibly, applicability to other European countries.
Some limitations should also be addressed. First, the
Dutch daily costs of mechanical ventilation and renal
replacement therapy had to be estimated, based on pub-
lished literature on ICU costs [13, 14]. Second, the time
horizon was limited to the hospital period and direct
medical costs, and thus, the economic consequences
could not be fully captured. One Swiss study, investigat-
ing out-of-pocket expenses of families with a child
spending > 4 days in the ICU reported mean 86 (±31)
Franc (converted ~ €137) per day, mainly on travel costs
and meals [27]. As such, the full impact of late initiation
of PN from a societal perspective could not be assessed.
Third, quality-adjusted life years (QALYs) were not used
as an outcome measure, as the time horizon was too
short (hospital stay) to meaningfully assess long-term
quality of life of critically ill children. It is acknowledged
that a cost-utility analysis is preferred over a cost-
effectiveness analysis, if a treatment has an impact on
health-related quality of life. At this time, a long-term
follow-up study is ongoing, with patients being evaluated
2 and 4 years after randomisation. This long-term
follow-up study includes an assessment of quality of life.
However, the aim of the current study was to perform a
cost-effectiveness analysis and not a cost-utility analysis,
which requires quality of life data. Finally, the lack of
detailed drug costs for Dutch patients may have
biased, and possibly underestimated, the differences in
drug costs.
Conclusion
The cost analyses showed that late initiation of PN reduced
the direct medical costs by 21% in critically ill children as
compared with early initiation of PN, beyond the expected
lower costs for the use of PN itself. Avoiding new infections
by late initiation of PN yielded a large cost reduction. With-
holding PN during the first week of critical illness in chil-
dren can thus be recommended both from a clinical and a
health-economic perspective.
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